

Maurizio Martelli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7663252/publications.pdf>

Version: 2024-02-01

76
papers

2,502
citations

361045

20
h-index

205818

48
g-index

76
all docs

76
docs citations

76
times ranked

4385
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. <i>Lancet Haematology</i> , 2020, 7, e737-e745.	2.2	430
2	Obinutuzumab or Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2017, 35, 3529-3537.	0.8	333
3	Diffuse large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2013, 87, 146-171.	2.0	323
4	A MALT lymphoma prognostic index. <i>Blood</i> , 2017, 130, 1409-1417.	0.6	149
5	Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. <i>Blood</i> , 2015, 126, 950-956.	0.6	138
6	Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. <i>Lancet Haematology</i> , 2017, 4, e15-e23.	2.2	106
7	Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL. <i>Blood</i> , 2019, 133, 919-926.	0.6	89
8	A randomized, open-label, Phase III study of obinutuzumab or rituximab plus CHOP in patients with previously untreated diffuse large B-Cell lymphoma: final analysis of GOYA. <i>Journal of Hematology and Oncology</i> , 2020, 13, 71.	6.9	82
9	Primary mediastinal large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 318-327.	2.0	77
10	Cytological diagnostic features of late breast implant seromas: From reactive to anaplastic large cell lymphoma. <i>PLoS ONE</i> , 2017, 12, e0181097.	1.1	72
11	Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2018, 132, 179-186.	0.6	63
12	Primary mediastinal large B-cell lymphoma. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 68, 256-263.	2.0	60
13	Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding. <i>Hematological Oncology</i> , 2018, 36, 624-632.	0.8	55
14	Langerhans' cell histiocytosis in adults. <i>Cancer</i> , 1997, 80, 1786-1791.	2.0	42
15	Positron Emission Tomography/Computed Tomography Assessment After Immunochemotherapy and Irradiation Using the Lugano Classification Criteria in the IELSG-26 Study of Primary Mediastinal B-Cell Lymphoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 42-49.	0.4	31
16	Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial. <i>Lancet Haematology</i> , 2021, 8, e34-e44.	2.2	29
17	Primary mediastinal lymphoma: diagnosis and treatment options. <i>Expert Review of Hematology</i> , 2015, 8, 173-186.	1.0	28
18	Effect of low or high doses of low molecular weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVID-19. <i>British Journal of Haematology</i> , 2020, 190, e214-e218.	1.2	25

#	ARTICLE	IF	CITATIONS
19	Chronic lymphocytic leukemia (CLL) in younger adults: A retrospective study of 133 cases. <i>Hematological Oncology</i> , 1989, 7, 127-137.	0.8	22
20	End-of-treatment PET/CT predicts PFS and OS in DLBCL after first-line treatment: results from GOYA. <i>Blood Advances</i> , 2021, 5, 1283-1290.	2.5	21
21	Total metabolic tumor volume as a survival predictor for patients with diffuse large B-cell lymphoma in the GOYA study. <i>Haematologica</i> , 2022, 107, 1633-1642.	1.7	21
22	The 68 Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	20
23	Extranodal Marginal Zone Lymphoma: Pathogenesis, Diagnosis and Treatment. <i>Cancers</i> , 2022, 14, 1742.	1.7	19
24	Prognostic impact of <i>TP53</i> mutation in newly diagnosed diffuse large B-cell lymphoma patients treated in the FIL-DLCL04 trial. <i>British Journal of Haematology</i> , 2022, 196, 1184-1193.	1.2	19
25	Langerhans' cell histiocytosis in adults. <i>Cancer</i> , 1997, 80, 1786-1791.	2.0	17
26	Impact of bone marrow biopsy on response assessment in immunochemotherapy-treated lymphoma patients in GALLIUM and GOYA. <i>Blood Advances</i> , 2020, 4, 1589-1593.	2.5	16
27	Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib. <i>Cancers</i> , 2021, 13, 3240.	1.7	16
28	Is now the time for molecular driven therapy for diffuse large B-cell lymphoma?. <i>Expert Review of Hematology</i> , 2017, 10, 761-774.	1.0	14
29	Baseline PET features to predict prognosis in primary mediastinal B cell lymphoma: a comparative analysis of different methods for measuring baseline metabolic tumour volume. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 46, 1334-1344.	3.3	14
30	Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience. <i>Annals of Hematology</i> , 2020, 99, 2405-2416.	0.8	11
31	Relapsed/refractory diffuse large B-cell lymphoma patients. A multicenter retrospective analysis of eligibility criteria for car-T cell therapy. <i>Leukemia and Lymphoma</i> , 2021, 62, 828-836.	0.6	11
32	Digital droplet PCR as a predictive tool for successful discontinuation outcome in chronic myeloid leukemia: Is it time to introduce it in the clinical practice?. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103163.	2.0	10
33	Single-nucleotide Fc γ 3 receptor polymorphisms do not impact obinutuzumab/rituximab outcome in patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 2935-2944.	2.5	10
34	Final Analysis of GOYA: A Randomized, Open-Label, Phase III Study of Obinutuzumab or Rituximab Plus CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4088-4088.	0.6	10
35	Reduced transmission of <i>Klebsiella pneumoniae</i> carbapenemase-producing <i>K. pneumoniae</i> (KPC-KP) in patients with haematological malignancies hospitalized in an Italian hospital during the COVID-19 pandemic. <i>JAC-Antimicrobial Resistance</i> , 2021, 3, dlab167.	0.9	9
36	The advantages and risks of ruxolitinib for the treatment of polycythemia vera. <i>Expert Review of Hematology</i> , 2020, 13, 1067-1072.	1.0	8

#	ARTICLE	IF	CITATIONS
37	Early Palliative Home Care versus Hospital Care for Patients with Hematologic Malignancies: A Cost-Effectiveness Study. <i>Journal of Palliative Medicine</i> , 2021, 24, 887-893.	0.6	8
38	BCL2 Expression in First-Line Diffuse Large B-Cell Lymphoma Identifies a Patient Population With Poor Prognosis. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, 267-278.e10.	0.2	8
39	The current role of interferon in hairy cell leukaemia: clinical and molecular aspects. <i>British Journal of Haematology</i> , 2021, 194, 78-82.	1.2	8
40	Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatment. <i>Blood Advances</i> , 2021, 5, 2945-2957.	2.5	7
41	Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors. <i>Hematological Oncology</i> , 2017, 35, 554-560.	0.8	6
42	Tyrosine kinase inhibitor discontinuation in the management of chronic myeloid leukemia: a critical review of the current practice. <i>Expert Review of Hematology</i> , 2020, 13, 1311-1318.	1.0	6
43	A prognostic model integrating PET-derived metrics and image texture analyses with clinical risk factors from GOYA. <i>EJHaem</i> , 2022, 3, 406-414.	0.4	6
44	Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. <i>Blood</i> , 2010, 116, 432-432.	0.6	5
45	Management of myelofibrosis and concomitant advanced cutaneous squamous cell carcinoma with ruxolitinib associated with cemiplimab. <i>Annals of Hematology</i> , 2021, 100, 2117-2119.	0.8	4
46	Real-life evaluation of potential candidates for treatment discontinuation in chronic myeloid leukemia: the impact of age and long-term follow-up. <i>Leukemia and Lymphoma</i> , 2021, 62, 1026-1027.	0.6	4
47	Real-life comparison of nilotinib versus dasatinib as second-line therapy in chronic phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2021, 100, 1213-1219.	0.8	4
48	Use of BTK inhibitors with focus on ibrutinib in mantle cell lymphoma: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 518-527.	0.8	4
49	Prognostic Value of Autoantibodies against Erythrocytes and Platelets in Chronic Lymphocytic Leukemia (CLL). <i>Tumori</i> , 1991, 77, 100-104.	0.6	3
50	Immunoglobulin kappa deleting element rearrangements are candidate targets for minimal residual disease evaluation in mantle cell lymphoma. <i>Hematological Oncology</i> , 2020, 38, 698-704.	0.8	3
51	Utility of procalcitonin and C-reactive protein as predictors of Gram-negative bacteremia in febrile hematological outpatients. <i>Supportive Care in Cancer</i> , 2022, 30, 4303-4314.	1.0	3
52	Use of BTK inhibitors with special focus on ibrutinib in Waldenström macroglobulinemia: An expert panel opinion statement. <i>Hematological Oncology</i> , 2022, 40, 332-340.	0.8	3
53	Hairy cell leukaemia with low CD103 expression: A rare but important diagnostic pitfall. <i>British Journal of Haematology</i> , 2022, 198, .	1.2	3
54	Switch from branded to generic imatinib: impact on molecular responses and safety in chronic-phase chronic myeloid leukemia patients. <i>Annals of Hematology</i> , 2020, 99, 2773-2777.	0.8	2

#	ARTICLE	IF	CITATIONS
55	Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome. <i>Haemophilia</i> , 2021, 27, e667-e674.	1.0	2
56	Acute promyelocytic leukemia (APL) in very old patients: real-life behind protocols. <i>Acta Oncologica</i> , 2021, 60, 1520-1526.	0.8	2
57	Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Patients: A Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2019, 134, 2888-2888.	0.6	2
58	Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. <i>British Journal of Haematology</i> , 2019, 186, e217-e219.	1.2	1
59	Residual Site Radiotherapy After Immunochemotherapy in Primary Mediastinal B-Cell Lymphoma: A Monoinstitutional Retrospective Study. <i>In Vivo</i> , 2020, 34, 1407-1413.	0.6	1
60	High Basal Maximal Standardized Uptake Value (SUVmax) in Follicular Lymphoma Identifies Patients with a Low Risk of Long-Term Relapse. <i>Cancers</i> , 2021, 13, 2876.	1.7	1
61	Interim Analysis of the IELSG-19 Randomised Study of Chlorambucil Alone Versus Chlorambucil Plus Rituximab Versus Rituximab Alone in Extranodal Marginal Zone Lymphomas of Mucosa-Associated Lymphoid Tissue (MALT lymphoma).. <i>Blood</i> , 2009, 114, 3939-3939.	0.6	1
62	Efficacy of ibrutinib as salvage treatment in a secondary central nervous system lymphoma (SCNSL) progressed after chemorefractory Primary Mediastinal B Cell Lymphoma (PMBCL). <i>Leukemia and Lymphoma</i> , 2021, , 1-4.	0.6	1
63	A Prognostic Model Integrating PET-Derived Quantitative Parameters and Image Texture Analyses Using Radiomics in a Large Prospective Phase III Trial, GOYA. <i>Blood</i> , 2019, 134, 883-883.	0.6	1
64	Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study. <i>Advances in Hematology</i> , 2022, 2022, 1-10.	0.6	1
65	Bing-Neel syndrome coexisting with oligodendroglioma. <i>Leukemia and Lymphoma</i> , 2022, 63, 2511-2514.	0.6	1
66	PET-CR as a potential surrogate endpoint in untreated DLBCL: meta-analysis and implications for clinical trial design. <i>Leukemia and Lymphoma</i> , 0, , 1-16.	0.6	1
67	Primary orbital lymphomas: Clinical findings and treatment in ten cases. <i>Orbit</i> , 1991, 10, 141-146.	0.5	0
68	In Reply to Adams and Kwee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 870-871.	0.4	0
69	Long-term follow-up of late chronic phase chronic myeloid leukemia patients treated with imatinib after interferon failure: a single center experience. <i>Leukemia and Lymphoma</i> , 2021, 62, 2261-2266.	0.6	0
70	Pharmacogenomic Markers of Clinical Efficacy in a Dose-Dense Therapy Regimen (R-CHOP14) in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2011, 118, 2478-2478.	0.6	0
71	Mantle CELL Lymphoma (MCL) in Elderly Patients (PTs): The Experience in Real-Life of Rete Ematologica Laziale Linfomi (RELLI). <i>Blood</i> , 2019, 134, 5257-5257.	0.6	0
72	Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design. <i>Blood</i> , 2019, 134, 4101-4101.	0.6	0

#	ARTICLE	IF	CITATIONS
73	Relapsed/Refractory Multiple Myeloma Patients. a Multicenter Retrospective Analysis of Eligibility Criteria for CAR-T Cell Therapy. <i>Blood</i> , 2021, 138, 3755-3755.	0.6	0
74	Long-Term Treatment of Hairy Cell Leukemia Patients with Interferon: Clinical and Molecular Aspects. <i>Blood</i> , 2020, 136, 37-37.	0.6	0
75	Obinutuzumab does not improve complete methabolic response but does not compromise mobilization or engraftment of autologous peripheral blood stem cells in diffuse large B cell lymphoma: Results from a fondazione italiana linfomi prospective phase II study (the GIOTTO study). <i>Hematological Oncology</i> , 2022, 40, 609-616.	0.8	0
76	Future Management Of Chronic Myeloid Leukemia: From Dose Optimization To New Agents. <i>Current Cancer Drug Targets</i> , 2022, 22, .	0.8	0